CLDN7 and ovarian carcinoma: Ovarian cancer showing higher expression of CLDN7 demonstrated lower sensitivity to platinum-based drugs, with increased sensitivity after knockdown of CLDN7, suggesting a direct role of CLDN7 in inducing drug resistance in ovarian cancer cells [21].